Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol
Purpose: Propranolol is the most widely used treatment for cardiovascular diseases. Dosage range in our patients is usually less than the amount mentioned in references. The aim of the present study was to clarify whether pharmacokinetic differences are able to justify the need for the fewer doses i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tabriz University of Medical Sciences
2017-06-01
|
| Series: | Advanced Pharmaceutical Bulletin |
| Subjects: | |
| Online Access: | http://journals.tbzmed.ac.ir/APB/Manuscript/APB-7-195.pdf |
| Summary: | Purpose: Propranolol is the most widely
used treatment for cardiovascular diseases. Dosage range in our patients is
usually less than the amount mentioned in references. The aim of the present
study was to clarify whether pharmacokinetic differences are able to justify
the need for the fewer doses in our patients or not.
Methods: Twenty
healthy volunteers (10 male) at heart center of Mazandaran University of
Medical Sciences were studied. Samples of blood were collected before a single
oral dose (40 mg) of Propranolol. Blood samples were taken up to 9 hours after
dose. Total plasma concentration of Propranolol was
measured by HPLC. Population Pharmacokinetic analysis was performed using
population pharmacokinetics modeling software P-Pharm.
Results: The mean value for oral plasma
clearance (CL/F) was 126.59 ml/hr. The corresponding values for apparent volume of distribution
(V/F), t1/2 beta, maximum blood concentration (C
max), and time to reach the maximum blood concentration (T max) were 334.12
Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively. The observed mean values
of V/F of propranolol in the present study were comparable with those reported
in the literature. However, the mean values of CL/F of propranolol in current
study was significantly higher than those reported in other population
(P-value<0.001).
Conclusion: This study has confirmed that the pharmacokinetic
differences are not able to justify over-responsiveness of Iranian population
to propranolol. Pharmacodynamic differences in responding to beta blocker drugs
by Renin secretion or having a different sensibility to beta receptors might
play a role in making our population have a different response to propranolol. |
|---|---|
| ISSN: | 2228-5881 2251-7308 |